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Abstract
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed
access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.
Methods: Pts with previously treated advanced or mRCC were eligible to receive nivolumab 3mg/kg every 2
weeks. Pts included in the analysis had received ≥1 dose of nivolumab and were monitored for drug-related
adverse events (drAEs) using CTCAE v.4.0. Immune-related (ir) AEs were defined as AEs displaying a certain, likely or
possible correlation with immunotherapy (cutaneous, endocrine, hepatic, gastro-intestinal and pulmonary). The
association between overall survival (OS) and irAEs was assessed, and associations between variables were
evaluated with a logistic regression model.
Results: A total of 389 pts were enrolled between July 2015 and April 2016. Overall, the objective response rate
was 23.1%. At a median follow-up of 12 months, the median progression-free survival was 4.5 months (95% CI 3.7–
6.2) and the 12-month overall survival rate was 63%. Any grade and grade 3–4 drAEs were reported in 124 (32%)
and 27 (7%) of pts, respectively, and there were no treatment-related deaths. Any grade irAEs occurred in 76 (20%)
of patients, 8% cutaneous, 4% endocrine, 2% hepatic, 5% gastro-intestinal and 1% pulmonary. Of the 22 drAEs
inducing treatment discontinuation, 10 (45%) were irAEs. Pts with drAEs had a significantly longer survival than
those without drAEs (median OS 22.5 versus 16.4 months, p = 0.01). Pts with irAEs versus without irAEs had a more
significant survival benefit (median OS not reached versus 16.8 months, p = 0.002), confirmed at the landmark
analysis at 6 weeks. The occurrence of irAEs displayed a strong association with OS in univariable (HR 0.48, p = 0.
003) and multivariable (HR 0.57, p = 0.02) analysis.
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Conclusions: The appearance of irAEs strongly correlates with survival benefit in a real-life population of mRCC pts
treated with nivolumab.
Keywords: Immunotherapy, Adverse events, Renal cell carcinoma, Expanded access trials,
Background
Nivolumab is a fully human monoclonal antibody target-
ing the programmed death receptor-1 (PD-1) and block-
ing the binding of PD-1, expressed on T cells, with its
ligands PD-L1 and PD-L2, present on antigen-presenting
cells and cancer cells [1]. Nivolumab therapy induces the
disruption of PD-1/PD-L1 signaling, thus restoring the
ability of T cells to selectively recognize and kill cancer
cells [2].
Regarding metastatic renal cell carcinoma (mRCC), in
a randomized phase III trial (CheckMate 025), nivolu-
mab compared with everolimus proved able to confer a
5.4-month improvement of median OS, with a more fa-
vorable safety profile [3, 4]. The magnitude of the clin-
ical benefit was so relevant that on November 2015 the
Food and Drug Administration (FDA) and on April 2016
the European Medical Association (EMA) approved
nivolumab for mRCC patients who had received a prior
line of treatment with anti-angiogenic agents (Adminis-
tration USFD, FDA Expands Use of Immunotherapeutic
to Kidney Cancer) [5, 6]. Afterwards, the Italian Renal
Cell Cancer Early Access Program (EAP) started in July
2015 based on such clinical data, during the evaluation
of nivolumab by EMA and the negotiations with the Ital-
ian Ministry of Health [7].
Immune-checkpoint inhibitors (ICIs) induce a peculiar
spectrum of toxicities, different from the one determined
by conventional chemotherapy, caused by an enhanced ac-
tivity of the immune system and by systemic inflammation:
the so-called “immune-related adverse events” (irAEs) [8].
These adverse events (AEs) display a wide variety of mani-
festations concerning grade of toxicity, generally mild al-
though severe cases may occur, as well as number and type
of organs involved. IrAEs could be dermatological (rash,
vitiligo and pruritus), gastrointestinal (diarrhea, colitis,
hepatitis, increase of amylase and lipase), endocrine (thy-
roiditis and hypophysitis), pulmonary (pneumonitis), renal
(nephritis) and systemic (fever and fatigue) [9].
In retrospective studies, non-conclusive evidence has
been collected about a possible association of the occur-
rence of irAEs with durable responses and survival bene-
fit from ICIs, both for anti-CTLA4 and anti-PD1, first in
advanced melanoma [10–15] and then in other tumor
settings, particularly non-small cell lung cancer
(NSCLC) [16–18]. Recently, a prospective clinical trial
demonstrated that, in NSCLC patients treated with nivo-
lumab, the early occurrence of irAEs (specifically rash
and pyrexia, but not diarrhea) correlated with an en-
hanced tumor response (37% vs 17%) and a longer
progression-free survival (PFS) (6.4 vs 1.5 months). The
authors reported a stronger predictive value for the de-
tection of toxicities at two weeks from the treatment
start, compared to the six-week assessment [19].
Given the controversy over the potential association of
irAEs with favorable clinical outcomes and the discord-
ant conclusions obtained in different cancer populations,
here we report the results of a secondary analysis of the
Italian EAP for nivolumab in mRCC patients, with the
specific aim to assess the correlation of AEs, specifically
irAEs, with patients’ outcome in this large real-life
mRCC population.
Patients and methods
Study population
From July 2015 to April 2016 nivolumab was provided
by BMS through the EAP in 95 hospitals in Italy. To-
tally, 490 requests were authorized, even though only
389 (80%) patients received at least one dose of nivolu-
mab in this program [7].
Patients aged ≥18 years affected by advanced or mRCC
that had relapsed after at least one prior therapy regimen
(including, but not limited to, sunitinib, sorafenib, pazo-
panib, axitinib, tivozanib, bevacizumab) in the advanced
or metastatic setting were considered eligible. Previous
treatments with cytotoxics, mTOR inhibitors and cyto-
kine therapy (e.g. IL-2, IFN), or vaccine therapy were
also permitted. No limitation was given to the number
of prior regimens. Any condition requiring systemic
treatment with either corticosteroids (> 10 mg daily
prednisone equivalent) or other immunosuppressive
medications within 14 days prior to the first dose of
study drug represented an exclusion criterion, while the
presence of asymptomatic brain metastases or requiring
systemic treatment with corticosteroids up to 10 mg
daily prednisone equivalent within 14 days prior to the
first dose of nivolumab was not. Mild impaired renal
function was allowed including serum creatinine ≤1.5 x
upper limit of normal or creatinine clearance ≥40mL/
min. Patients with active known or suspected auto-
immune disease were excluded. All the patients included
were requested to sign and date a written informed con-
sent form provided by the company (BMS). The EAP re-
ceived the approval by the Ethics Committee of each
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Center included in the program. All data presented here
were prospectively collected on electronic patient files.
Treatment modalities
Patients were administered treatment with nivolumab 3
mg/kg intravenously every 2 weeks until disease progres-
sion (PD), unacceptable toxicity, consent withdrawal, or
physician’s decision based on clinical data.
Safety assessments were performed within 72 h prior
to each nivolumab administration or as required by local
standard of care procedures and included physical as-
sessment and complete blood tests (hematology, renal
and hepatic function, pancreatic enzymes and hormonal
levels, specifically thyroid function testing including
TSH reflex to free T3 and free T4 in case of abnormal
result). Drug-related AEs (drAEs) were defined as all the
AEs that the investigators classified as potentially related
to treatment. Their incidence, grade and characteristics
were obtained from patient clinical files and laboratory
reports and classified according to the Common Ter-
minology Criteria for AEs v4.0 (CTCAEs). Furtherly, the
EAP investigators classified a subgroup of drAEs as
irAEs, if they displayed a certain, likely or possible cor-
relation with an immune-related pathogenesis, specific-
ally considering five categories: cutaneous (rash/
inflammatory dermatitis, bullous dermatosis, severe cu-
taneous adverse reactions, pruritus, vitiligo), endocrine
(increased and/or decreased function of endocrine
glands: thyroid, hypophysis and hypothalamic-pituitary
axis, gonads, adrenal glands and pancreas), hepatic
(hypertransaminasemia and hepatitis), gastro-intestinal
(diarrhea, colitis, increased amylase and lipase) and pul-
monary (pneumonitis, interstitial lung diseases, bron-
chiolitis obliterans organising pneumonia) toxicity.
Endpoints
The primary endpoint of Italian EAP for nivolumab in
mRCC was to assess the safety and efficacy of this agent
in a real-world setting. The secondary endpoint was to
assess the incidence of irAES in the real-life mRCC
population treated with nivolumab, as well as the poten-
tial association of irAEs with patients’ outcome in terms
of overall survival (OS).
Statistical analysis
Data were summarized by frequency for categorical vari-
ables and by median and range for continuous variables.
Continuous variables were compared using the Wil-
coxon test. Association between categorical variables
was assessed using the Fisher exact or the chi-square
test, as appropriate. Differences were considered statisti-
cally significant when p < 0.05. PFS was calculated from
the start of nivolumab until disease progression or death
(whichever occurred first) or censored at the time of last
follow-up. Patients discontinuing for toxicity were cen-
sored at the initiation of the subsequent therapy if still
on response. OS was calculated from the start of nivolu-
mab until death or censored at the time of last
follow-up. Patients lost to follow-up were censored at
the time of last contact. The Kaplan-Meier method was
used to estimate PFS and OS. In order to minimize the
bias related to drug exposure according to treatment
duration, a landmark analysis at the median time appear-
ance of AEs was performed. The log-rank test and Cox
proportional hazards regression were used to test for dif-
ferences between groups and to estimate hazard ratios
and their 95% confidence intervals. Afterwards, univari-
able analysis a multivariable analysis was carried out by
Cox regression model. When considering incidence of
AEs, a logistic model was used to test associations with
patients’ characteristics. In both regressions, only factors
with a P value < 0.10 at the univariable analysis were in-
cluded in the multivariable option. Multivariable analysis
was implemented in a stepwise selection approach based
on Wald statistics, with enter and remove P values set to
0.05 and 0.10, respectively. All statistical analyses were
carried out with IBM-SPSS Statistical Software (IBM
SPSS Statistics for Windows, Version 21.0. Armonk,
NY).
Results
A total of 389 patients were enrolled between July 2015
and April 2016 and treated with at least 1 dose of nivo-
lumab, thus they represented the study population for
this analysis. Baseline patients’ characteristics are re-
ported in Table 1. The median follow-up was 11.9
months (range 1–24.7 months) and patients were admin-
istered a median of 13 doses of nivolumab (range 1–49
doses).
Specific details regarding drAEs reported in the Italian
EAP and in the Checkmate 025 trial are shown in
Table 2. Any grade and grade 3–4 drAEs occurred in
124 (32%) and 27 (7%) of patients in Italian EAP, re-
spectively. No treatment-related deaths were recorded.
Median time to appearance of drAEs was 1.4 months
(range 0–11.4 months) and they were generally manage-
able with treatment as per protocol-specific guidelines.
DrAEs represented the reason for treatment
discontinuation in 22 cases (7.9%), of which 10 (45%)
were considered irAEs, including: grade 4 hyperglicemia
(n = 1), grade 3 diarrhea (n = 1), grade 3 pneumonitis
(n = 1), grade 3 bronchiolitis obliterans organising
pneumonia (BOOP), grade 3 fatigue (n = 1), grade 3 skin
toxicity (n = 1), grade 3 tremor (n = 1), grade 2 eyelid
ptosis (n = 2), grade 2 liver toxicity (n = 1), grade 2
hypothyroidism (n = 1).
Regarding irAEs, any grade irAES occurred in 76
(20%) patients, of which 40 (10%) grade 1, 27 (7%) grade
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2, 9 (2%) grade 3 and 1 (< 1%) grade 4 AEs, respectively.
Considering the five pre-specified categories, 30 irAEs
(8%) were cutaneous, 17 (4%) endocrine, 7 (2%) hepatic,
19 (5%) gastro-intestinal and 4 (1%) pulmonary. Further
details are illustrated in Table 3.
At a median follow-up of 12 months, the median PFS
was 4.5 months (95% CI 3.7–6.2 months) and the 1-year
OS rate was 63% in the overall study population. In pa-
tients with and without drAEs, median OS was 22.5
months (95% CI not yet evaluable) versus 16.4 months
(95% CI 12.1–20.7 months), 1-year OS was 69.0% versus
59.7% and 2-year OS was 46.6% versus 43.6%, respect-
ively, p = 0.01 (Additional file 1: Figure S1A). In patients
who discontinued treatment for the occurrence of
drAEs, 1-year OS was 65%. A similar significant result
was obtained considering selectively the population with
the occurrence of irAEs (n = 76) versus no reported
irAEs, where median OS was not reached versus 16.8
months (95% CI 13.0–20.6 months), 1-year OS was
75.4% versus 59.8% and 2-year OS was 66.9% versus
36.8%, respectively, p = 0.002 (Fig. 1a).
In order to minimize the bias related to drug exposure
according to treatment duration, a landmark analysis at
the median time appearance of AEs (6 weeks) was per-
formed for OS. The appearance of drAEs showed a
non-significant trend towards a prolonged OS (p = 0.71)
(Additional file 1: Figure S1B) while irAEs retained their
statistically significant association with improved OS (p
= 0.006) (Fig. 1b).
In univariable model, a significant association between
drAEs and prolonged OS was shown, with HR 0.64 (95%
CI 0.46–0.91, p = 0.01) and, considering selectively pa-
tients experiencing irAEs, the correlation resulted to be
stronger, with HR 0.48 (95% CI 0.30–0.78, p = 0.003). In
a multivariable model, the significant association be-
tween irAEs and increased OS was confirmed, with HR
0.57 (95% CI 0.35–0.93, p = 0.02) (Table 4). A Cox re-
gression analysis was used to estimate the association
between survival and the available patients’ variables.
Also, a variable related to the duration of treatment was
considered in order to better understand the relationship
between toxicity and OS, to confute the hypothesis that
patients showing toxicity may be less or more treated
than the others. Choosing 4 nivolumab doses as cut-off
(corresponding to 6 weeks completed, the median time
of appearance of AEs) the occurrence of a toxicity event
maintains its prognostic role (Table 4).
Considering the association of OS with the five
pre-specified categories of irAEs, endocrine, cutaneous
and gastrointestinal irAEs were associated with an im-
proved OS (1-year OS 92.3, 81.6 and 78.6%, respect-
ively), while hepatic and pulmonary irAEs conditioned a
poor OS outcome (1-year OS 42.9 and 25.0%, respect-
ively) (p = 0.001), confirmed at landmark analysis at 6
Table 1 Baseline patients characteristics
Characteristic N (%)
Age
< 75 years 319 (82.0)
≥ 75 years 70 (18.0)
Median (range) age, years 65 (34–85)
Gender
Male 291 (74.8)
Female 98 (25.2)
ECOG performance status
0 176 (47.1)
1 174 (46.5)
2 24 (6.4)
NA 15
IMDC prognostic group
Favourable 62 (20.2)
Intermediate 212 (69.1)
Poor 33 (10.7)
NA 82
Nephrectomy
Yes 369 (94.9)
No 20 (5.1)
Histology
Clear-cell 356 (91.5)
Non-clear-cell 26 (6.7)
Undifferentiated/Unknown 7 (1.8)
Metastasis site
Lung 286 (73.5)
Lymph node 238 (69.2)
Bone 193 (49.6)
Liver 128 (32.9)
Brain 32 (8.2)
Number of prior systemic therapies
1 80 (20.7)
2 137 (35.4)
≥ 3 170 (43.9)
First-line therapy
Sunitinib 261 (67.4)
Pazopanib 80 (20.7)
Other 46 (11.9)
Prior everolimus
Yes 163 (42.1)
No 224 (57.9)
Abbreviations: N number, NA not assessed, ECOG Eastern Cooperative
Oncology Group, IMDC International Metastatic Renal Cell Carcinoma
Database Consortium
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weeks, although the analysis was limited by the low
numbers.
We analyzed the association with OS of drAEs and
irAEs stratified for low grade (G1 and G2) and high
grade (G3 and G4): 1-year OS in high versus low grade
was 41.3% vs 75.5%, HR 2.44 (95% CI 1.26–4.72, p =
0.006) for drAEs, and 60.9% vs 79.6% HR 1.90 (95% CI
0.72–5.02, p = 0.19) for irAEs. Additionally, early onset
(< 6 weeks) versus late onset (> 6 weeks) drAEs and
irAEs showed 1-year OS rates of 70.7% vs 79.8% HR
1.96 (95% CI 0.87–4.43, p = 0.10) and 78.7% vs 85.2%,
HR 1.76 (95% CI 0.54–5.74, p = 0.34), respectively.
Discussion
We performed this analysis in order to assess the safety
and efficacy of nivolumab in mRCC patients in the
real-world setting in Italy, in an Early Access Program,
and the potential association between irAEs and survival
outcome.
Nivolumab proved to be safe and well-tolerated in the
routine clinical practice. The most common drAEs oc-
curred were fatigue, rash, diarrhea, thyroid disfunctions,
both hypothyroidism and hyperthyroidism, and pyrexia,
consistently with previous literature evidences regarding
nivolumab treatment, including a recent pooled analysis
on the safety profile of nivolumab in patients with ad-
vanced melanoma [15].
Table 2 Rates of drug-related adverse events reported in the CheckMate 025 trial and in the Italian Early Access Program of
nivolumab in mRCC
CheckMate025 Italian EAP
Everolimus N = 397 Nivolumab N = 406 Nivolumab N = 389
Any grade Grade≥ 3 Any grade Grade≥ 3 Any grade Grade≥ 3
Treatment-related AEs, % 88 37 79 19 32 7
Fatigue 34 3 33 2 13 2
Pyrexia NR NR NR NR 3 0
Nausea 17 1 14 < 1 0 0
Pruritus 10 0 14 0 0 0
Diarrhea 21 1 12 1 5 1
Decreased appetite 21 1 12 < 1 1 < 1
Rash 20 1 10 < 1 9 < 1
Hypothyroidism NR NR NR NR 2 0
Hyperthyroidism NR NR NR NR 2 0
Hypophisitis NR NR NR NR < 1 < 1
Hypertransaminasemia NR NR NR NR 1 0
Cough 19 0 9 0 0 0
Anemia 24 8 8 2 2 < 1
Dyspnea 13 < 1 7 1 3 1
Edema peripheral 14 < 1 4 0 0 0
Pneumonitis 15 3 4 1 2 < 1
Mucosal inflammation 19 3 3 0 0 0
Dysgeusia 13 0 3 0 0 0
Hyperglycemia 12 3 2 1 < 1 < 1
Stomatitis 29 4 2 0 0 0
Hypertriglyceridemia 16 4 1 0 0 0
Epistaxis 10 0 1 0 0 0
Abbreviations: NR not reported, N number, AEs adverse events, EAP Early Access Program
Table 3 Rates of irAEs in the Italian Early Access Program of
nivolumab in mRCC
irAEs G1
N (%)
G2
N (%)
G3
N (%)
G4
N (%)
Any grade
N (%)
Cutaneous 16 (4) 12 (3) 2 (1) 0 30 (8)
Endocrine 10 (3) 5 (1) 1 (< 1) 1 (< 1) 17 (4)
Hepatic 5 (1) 2 (1) 0 0 7 (2)
Gastro-intestinal 8 (2) 7 (2) 4 (1) 0 19 (5)
Pulmonary 1 (< 1) 1 (< 1) 2 (1) 0 4 (1)
Abbreviations: N number, irAEs immune-related adverse events
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Interestingly, in our analysis we found a lower rate
of drAEs in the Italian EAP, both any grade and
grade ≥ 3, as compared to those of the nivolumab arm
of the clinical trial Checkmate 025 [3, 4, 7]. These
findings highlight the importance of real-world data
since they are able to give key messages about the ef-
ficacy and safety results of new anti-cancer agents in
the routine clinical practice, thus helping the develop-
ment and the management of drugs.
We showed that patients reporting treatment-related
toxicity had a significantly longer OS. The most remark-
able finding is that the selection of AEs potentially deter-
mined by the nivolumab-related immune system
activation, the irAEs, leads to observe a stronger
Fig. 1 Survival analysis for immune-related adverse events. Kaplan-Meier curves for overall survival in patients stratified for the occurrence of
immune-related adverse events (a) and with landmark analysis at 6 weeks (b)
Table 4 Cox model of association of baseline characteristics with overall survival
Characteristic Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age, years
≥ 75 vs < 75 0.62 (0.39–0.98) 0.04 0.55 (0.35–0.87) 0.01
Gender
Male vs female 1.18 (0.82–1.71) 0.36 –
Metastatic site, yes vs no
Bone 1.35 (0.99–1.84) 0.06 –
Liver 1.05 (0.76–1.46) 0.75 –
CNS 1.39 (0.84–2.31) 0.20 –
Number of prior therapies
> 1 vs 1 1.80 (1.15–2.87) 0.01 –
First line
Sunitinib vs pazopanib 1.24 (0.84–1.84) 0.28
Prior everolimus
Yes vs no 1.30 (0.95–1.76) 0.10
Drug-related toxicity (drAEs)
Yes vs no 0.64 (0.46–0.91) 0.01 –
Ir toxicity (irAEs)
Yes vs no 0.48 (0.30–0.78) 0.003 0.57 (0.35–0.93) 0.02
Number of Nivolumab doses
> 4 vs ≤4 0.11 (0.08–0.15) < 0.0001 0.11 (0.08–0.15) < 0.0001
Abbreviations: CI confidence interval, HR hazard ratio, CNS central nervous system
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association with an improved survival, confirmed in a
multivariable model.
Several studies have reported a potential association
between the occurrence of irAEs during immunotherapy
and treatment efficacy. First, in the setting of advanced
melanoma, the development of irAEs in patients treated
with CTLA4 inhibitors proved to be significantly corre-
lated with higher tumor response rate and probability of
survival [10–13, 20]. Similarly, during treatment with
nivolumab, patients experiencing any grade of irAEs dis-
played a significant overall survival (OS) improvement
[14], whereas in a recent study any grade irAEs were as-
sociated with an increased overall response rate (ORR)
but not with longer progression free survival (PFS) [15].
Afterwards, similar evidences were collected in
non-small cell lung cancer (NSCLC) patients treated
with nivolumab, where those experiencing irAEs had a
higher ORR and an increased PFS, thus identifying the
occurrence of irAEs as an independent predictor of
treatment response [18]. Nevertheless, other evidences
did not support the correlation between immune-related
toxicity and benefit from immunotherapy. Specifically, in
two cohorts of patients affected by metastatic melanoma
treated with ipilimumab, the incidence of irAEs and the
use of systemic corticosteroids to treat immune-related
toxicity were not found to be associated with ORR, OS
and time to treatment failure [21, 22].
Our findings support the association between irAEs
and survival benefit from nivolumab. However, one of
the possible bias of this analysis is the influence of treat-
ment duration, since its increase leads to a prolonged
nivolumab exposure and therefore to a potentially higher
likelihood of AEs occurrence. To this purpose, we per-
formed a landmark analysis at the median time of ap-
pearance of AEs, 6 weeks, and the association of irAEs
occurrence with an improved OS was confirmed. Add-
itionally, early versus late onset irAEs, defined as occur-
ring before or after the cutoff of 6 weeks from the
treatment start, showed a non-significant trend towards
a poorer OS, however further studies should collect
more solid evidence about this topic.
Interestingly, two recent studies obtained different re-
sults according to the intensity of the toxicity. Recently
Judd et al, in a retrospective series of non-melanoma pa-
tients treated with anti-PD-1 agents obtained a trend to-
wards an improved ORR in patients experiencing any
irAE, but this association was statistically significant for
low grade irAEs [23]. It confirmed the previous data by
Weber et al, showing that in the setting of melanoma pa-
tients who received nivolumab monotherapy, those with
any grade irAEs had a significantly better ORR, while for
G3–4 irAEs this correlation was not significant [15].
This could reflect the tumor biolological aggressiveness,
or, on the other side, it may be explained by the negative
effects of high grade AEs, potentially dangerous or able
to impair the adequate assessment of tumor response. In
our results, G3–4 drAEs were significantly associated
with a lower 1-year OS rate as compared to G1–2
drAEs, while G3–4 versus G1–2 irAEs showed a
non-significant trend towards a shorter survival
outcome.
The reasons underlying this potential association be-
tween irAEs occurrence and patients’ outcome are still
to be determined, although some hypotheses have been
advanced. IrAEs are caused by the unbalancing of the
immune system induced by immune checkpoint block-
ade, possibly generated by the cross-reactivity between
tumor neoantigens and normal tissue antigens [24].
These shared antigens could be involved in this process,
although this seems not to be a convincing explanation
in light of the low incidence rate of multiple irAEs in the
same patient. Other possible mechanisms were postu-
lated concerning anti-CTLA4 antibodies: on the one side
the role of immunosuppressive regulatory T cells (T reg)
is questioned, on the other ipilimumab could induce a
non-specific increase in endogenous T-cell response me-
diated by dendritic cells or paracrine cytokine stimula-
tion. Another interesting theory advocates a potential
causality of this association irAEs-treatment efficacy due
to the interaction between immunotherapy and poly-
morphisms in the genes involved in the response to ICIs
[25]. Finally, considering anti-PD-1/PDL-1 inhibitors,
they are deeply involved in the regulation of humoral
immune response, since they proved able to modulate B
cells both directly and via T-cell mediation. The altered
production of auto-antibodies could in turn mediate the
development of irAEs, thus possibly explaining the asso-
ciation between immune-related toxicity and treatment
response [26]. A possible evidence in support of this hy-
pothesis is the finding that the presence of
pre-treatment anti-thyroid antibodies is an independent
predictor of response to nivolumab in NSCLC patients
[18].
Another key point is the definition of irAEs, since no
well-established criteria have been identified yet and lit-
erature evidences are not clear upon this topic. We de-
cided to select five distinct categories of irAEs
(cutaneous, endocrine, hepatic, gastro-intestinal and pul-
monary), according to the best known pathogenetic cor-
relation between toxicity and immunotherapy. However,
further studies focusing specifically on the mechanisms
of action of ICIs could better clarify which AEs should
be considered immune-related. The highest level of evi-
dence collected in other disease settings regarding the
association of irAEs with response to immunotherapy is
about cutaneous toxicity, especially vitiligo, followed by
endocrine alterations. Specifically, in melanoma patients,
cutaneous irAEs were shown to be associated with
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clinical benefit and better outcome from anti-PD-1 treat-
ment, with a major role of vitiligo [27–29] and in NSCLC
dermatological and endocrine irAEs, specifically
antibody-mediated thyroid disfunctions, resulted to be posi-
tively correlated with tumor responses or improved survival
to anti-PD-1 ICIs [16, 17]. Although limited by the small
numbers, we observed that cutaneous, endocrine and
gastro-intestinal irAEs were significantly associated with
improved OS, similarly to unselected irAEs, while hepatic
and pulmonary irAEs conditioned a poor OS outcome.
Nevertheless, no definitive conclusions could be derived
from these results, considering the limited number of pa-
tients experiencing any specific class of irAEs.
At our knowledge, this is the first study investigating
the potential association of irAEs with survival in the
setting of mRCC. Our results highlight the importance
to recognize treatment-related toxicities, specifically
those potentially underlying immune-related mecha-
nisms, since these display a significant association with
an improved patients’ outcome from immunotherapy
with anti-PD-1 ICIs. The limitations of this study are in-
herent to the specific nature of EAP, basically the high
heterogeneity of the patients’ population and its retro-
spective nature, that could have impaired the power of
the statistical analysis and limited to drive robust con-
clusions upon the results achieved. Moreover, as previ-
ously discussed, a precise definition and categorization
of irAEs is still lacking, and the classification that we
performed is not validated or standardized.
In conclusion, the appearance of irAEs strongly corre-
lates with a survival benefit in a real-life population of
mRCC patients treated with nivolumab. Further studies
could confirm the potential role of the incidence of
irAEs as a predictor of response to ICIs as well as ex-
plore the underlying mechanisms leading to the develop-
ment of immune-related toxicity. As a consequence,
criteria should be identified to establish whether a pre-
cise timing of occurrence of irAEs or specific
organ-related toxicities could better predict the treat-
ment outcome, with the aim to better personalize the
treatment management in this disease setting.
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